SCPH

About scPharmaceuticals Inc.

scPharmaceuticals Inc. is a pharmaceutical firm dedicated to developing and commercializing a variety of medicinal products. Its primary investigational therapy, FUROSCIX, is a specialized formulation of furosemide delivered through an on-body infusor, intended for managing congestion in heart failure patients. The company's pipeline also encompasses scCeftriaxone, an antibiotic aimed at treating infections caused by both gram-positive and gram-negative bacteria, as well as the scCarbapenem program, another antibiotic designed for gram-negative bacterial infections. Additionally, scPharmaceuticals has entered into a collaboration agreement with West Pharmaceutical Services, Inc. for the advancement of a single-use SmartDose device. Founded in 2013, the company's main operations are based in Burlington, Massachusetts.

CEO: John H. Tucker
IPO Date: Nov 17, 2017

Market Data

Open: $5.67
High: $5.67
Low: $5.67
Volume: 10.9M
Avg Volume: 1.4M
52W High: $6.28
52W Low: $1.94

Valuation

Market Cap: $302M
Enterprise Value: $314M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-71M
Revenue: $36M
Net Income: $-85M
Cash: $76M
Debt: $53M

Events

EarningsNov 12

EPS est. -0.25 · actual -0.37